Hemispherx Biopharma Inc., of Philadelphia, said it inked an agreement with Emerge Health Pty Ltd., of Australia, to file for approval of Alferon N Injection in Australia and New Zealand and begin distribution in those countries on a named-patient basis, where appropriate. Under the terms, Emerge will coordinate regulatory-compliant programs to inform physicians about Alferon, and Hemispherx will support those programs. Financial details were not disclosed.